The collaboration of local producers with innovator companies is essential but it is not happening at visible scale.
What are the barriers to collaboration and how can they be removed?
What opportunities are presented by collaboration between would-be competitors?
What benefits accrue to governments and patients when there is collaboration?
What incentives are available to local producers and how can they be accessed?
In this panel, GSK (UK) will discuss some strategies for possible hookups with local manufacturers around the manufacture of chlorhexidine for neonatal use.
Speakers – SAGMA, GSK (UK), USP, Department of Trade, Regulators.